Drug therapy in pregnancy: The lessons of diethylstilbestrol, thalidomide, and Bendectin
- 1 January 1990
- journal article
- review article
- Published by Taylor & Francis in Health Care for Women International
- Vol. 11 (4) , 423-432
- https://doi.org/10.1080/07399339009515912
Abstract
A pregnant woman and the fetus she carries face health risks from many sources. One risk that requires ongoing vigilance is the use of prescription drugs during pregnancy. The international health care community has been sensitized to the risks of drug use during pregnancy because of three Pharmaceuticals that have caused widespread crises for mothers and their offspring. The crises that diethylstilbestrol, thalidomide, and, to a lesser extent, Bendectin have created in the past four decades are reviewed in this article. The lessons these drug crises can teach us are articulated in the belief that similar crises may be averted in the future.Keywords
This publication has 13 references indexed in Scilit:
- The New TeratogensMCN: The American Journal of Maternal/Child Nursing, 1989
- Teratogen update: Clinical aspects of thalidomide embryopathy—A continuing preoccupationTeratology, 1985
- Males exposed in utero to diethylstilbestrolJAMA, 1984
- Breast Cancer in Mothers Given Diethylstilbestrol in PregnancyNew England Journal of Medicine, 1984
- A randomized double‐blind controlled trial of the value of stilboestrol therapy in pregnancy: long‐term follow‐up of mothers and their offspringBJOG: An International Journal of Obstetrics and Gynaecology, 1983
- Teratogen update: BendectinTeratology, 1983
- The Bendectin Saga: Another American Tragedy (Brent, '80)Teratology, 1983
- THALIDOMIDE AND FEMALE GENITAL MALFORMATIONS?The Lancet, 1976
- The lesson of thalidomideClinical Pharmacology & Therapeutics, 1973
- The Thalidomide Tragedy in Germany: The End of a Historic Medicolegal TrialNew England Journal of Medicine, 1971